GlassScriptPhysician profile
Sanjiva Goyal
NPI 1558350702
$7,534.29
in general payments reported to CMS, 2019-2025
27 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $1,084 · 2021: $831 · 2022: $860 · 2023: $1,230 · 2024: $1,450 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,857 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,857.41 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,546.22 | 2019-2025 | |
| Janssen Biotech, INC. | $934.11 | 2019-2025 | Tremfya, Simponi, Stelara |
| Galderma Laboratories, L.P. | $629.33 | 2019-2025 | Nemluvio, Twyneo |
| Genzyme Corporation | $593.22 | 2019-2025 | |
| Leo Pharma INC. | $516.53 | 2019-2025 | Adbry |
| Amgen INC. | $490.91 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $398.36 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $323.46 | 2019-2024 | Ilumya |
| Incyte Corporation | $273.62 | 2021-2025 | Opzelura |
| Pfizer INC. | $269.03 | 2019-2025 | |
| Lilly USA, LLC | $249.50 | 2019-2025 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $197.05 | 2022-2025 | Dupixent, Libtayo |
| Almirall LLC | $192.87 | 2019-2025 | Klisyri |
| Allergan, INC. | $165.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $127.92 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $111.07 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Verrica Pharmaceuticals INC. | $91.91 | 2023-2025 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $85.53 | 2019-2023 | Valchlor |
| Ucb, INC. | $64.86 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.10 | 2019-2025 | Cabtreo |
| Mylan Pharmaceuticals INC. | $30.89 | 2019 | |
| Dermira, INC. | $28.17 | 2020-2021 | |
| Aclaris Therapeutics, INC. | $24.98 | 2019 | |
| Encore Dermatology INC. | $22.28 | 2019 | |
| Lnhc, INC | $17.72 | 2025 | Zelsuvmi |
| Botanix Sb INC | $16.89 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjiva Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.